Article Text

Download PDFPDF
Correspondence
CT screening for lung cancer
  1. Robert P Young,
  2. Raewyn J Hopkins
  1. Schools of Biological Sciences and Health Sciences, University of Auckland, Auckland, New Zealand
  1. Correspondence to Dr Robert P Young, Director, Respiratory Genetics Group, Schools of Biological Sciences and Health Sciences, University of Auckland, PO Box 26161, Epsom 1344, Auckland, New Zealand; roberty{at}adhb.govt.nz

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the recent opinion piece by Field et al1 outlining plans for a CT screening trial in the United Kingdom (the UK Lung Screen (UKLS)) following the results of the National Lung Cancer Screening Trial. We agree that cost-effectiveness and defining who would most likely benefit from CT screening remain key issues to be resolved before CT screening can be offered routinely in clinical practice.2

First, cost-effectiveness is most likely to be achieved through optimising the risk assessment of those potentially eligible for CT …

View Full Text

Footnotes

  • Linked articles 200762, 200822.

  • Funding RPY, and his research, is supported by grants from the University of Auckland, Health Research Council of New Zealand and Synergenz Bio Sciences Ltd.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles

  • PostScript
    John Field David Baldwin Kate Brain Anand Devaraj Tim Eisen Stephen W Duffy David M Hansell Keith Kerr Richard Page Mahash Parmar David Weller David Whynes Paula Williamson
  • PostScript
    Naveen Dutt Deepak T Hari